CPX-351 as first-line treatment in AML: Real-world data

https://is1-ssl.mzstatic.com/image/thumb/Podcasts125/v4/ac/db/b3/acdbb369-23a5-f4ef-1717-3b6405d74b6f/mza_5928252466954251512.jpeg/600x600bb.jpg

AML Hub

Scientific Education Support

29 episodes

1 week ago

The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.

Hosted on Acast. See acast.com/privacy for more information.

Education

RSS

All content for AML Hub is the property of Scientific Education Support and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Hosted on Acast. See acast.com/privacy for more information.

Education

https://assets.pippa.io/shows/undefined/1585645708468-f1820b05797bc1563ae18cf50ab2ecce.jpeg

CPX-351 as first-line treatment in AML: Real-world data

AML Hub

16 minutes 36 seconds

1 year ago

CPX-351 as first-line treatment in AML: Real-world data

Here, we summarize five real-world studies presented at EHA 2024 on real-world outcomes of patients with AML who received CPX-351 as a first-line treatment.

Hosted on Acast. See acast.com/privacy for more information.